Tuesday, May 1, 2018 Dinner Short Course: 6:00-8:30
SC9: CAR T Cell Therapy for Solid Tumors
Instructors:
Tara Arvedson, Ph.D., Director, Oncology Research, Amgen
Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital, Harvard Medical School
Moonsoo M. Jin, PhD, Associate Professor, Molecular Imaging Innovations Institute, Radiology, Weill Cornell Medical College
Course Outline:
6:00 Course Introduction
Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital, Harvard Medical School
6:40 Dinner Break
7:00 Strategies to Enhance Efficacy and Safety: Effect of CAR Affinity and PET/CT Imaging of T Cell Activity
Moonsoo M. Jin, PhD, Associate Professor, Molecular Imaging Innovations Institute, Radiology, Weill Cornell Medical College
In this course, I’ll discuss the influence of CAR affinity on selecting CAR T cytotoxicity against target cells with varying levels of antigen expression. I’ll also present our new PET/CT imaging technique to determine T cell distribution, and how T cell expansion and contraction dynamics relates to T cell efficacy and toxicity.
7:40 Bispecific T Cell Engaging Antibodies in Hematologic and Solid Tumor Malignancies
Tara Arvedson, Ph.D., Director, Oncology Research, Amgen
A bispecific T cell engaging antibody (BiTE®) targeting CD19 has been approved for use in acute lymphoid leukemia. Based on the success of this molecule, BiTE® antibody constructs and other T cell engaging molecules are being evaluated in hematologic and solid tumor malignancies. This presentation will discuss preclinical activity of T cell engaging constructs and strategies used to maximize clinical efficacy.
8:20 Panel Discussion with Course Instructors
8:30 End of Course
Instructor Biographies
Tara Arvedson, Ph.D., Director, Oncology Research, Amgen
Tara Arvedson is a researcher and team leader in the Oncology Research department at Amgen. She received her Ph.D. at Caltech and was later a Damon Runyon Cancer Research Fellow at UC San Diego. Since being at Amgen she has led multiple programs targeting benign and malignant hematology using both large and small molecules. These programs have progressed from discovery stage to the clinic.
Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital, Harvard Medical School
Soldano Ferrone received his MD and PhD degrees in 1964 and in 1971, respectively, from the University of Milan, Milan, Italy. He has held faculty positions at the University of Milan, Milan, Italy, Scripps Clinic and Research Foundation, La Jolla, CA, Columbia University, New York, NY, New York Medical College, Valhalla, NY, Roswell Park Cancer Institute, Buffalo, NY and at the University of Pittsburgh School of Medicine, Pittsburgh, PA. Since 2012 he is a faculty member of the Department of Surgery at Massachusetts General Hospital, Harvard Medical School, Boston, MA. Dr. Ferrone has received many awards and honors. For the last 30 years he has been the member of many review committees including NIH Study Sections, and of the editorial boards of many scientific journals. Furthermore, he is the member of several external scientific advisory boards. Dr. Ferrone’s research program focuses on the molecular characterization of escape mechanism(s) utilized by tumor cells to avoid immune recognition and destruction and on the development of combinatorial immunotherapeutic strategies to counteract the escape mechanism(s) utilized by tumor cells. These studies are greatly facilitated by the large panel of HLA antigen- and human tumor antigen-specific monoclonal antibodies he has developed and shared with the scientific community over the years. He has described the results of his studies in more than 600 papers published in peer reviewed journals. Moreover, he has been the editor of 14 books and the guest editor of 5 special issues of oncology journals.
Moonsoo M. Jin, PhD, Associate Professor, Molecular Imaging Innovations Institute, Radiology, Weill Cornell Medical College
Dr. Jin is currently Associate Professor at Radiology Department at Weill Cornell Medicine in New York. His lab is part of Molecular Imaging Innovation Institute, and a member of Meyer Cancer Center. His current research includes development of novel CAR T technology and whole body imaging of T cells and antibodies, and engineering of novel antibody formats for imaging and therapy applications. He has founded a biotech company, AffyImmune Therapeutics, Inc., which plans to commence a clinical trial using CAR T cells against refractory thyroid cancer. He has received numerous awards including New Investigator Recognition Award by Orthopedic Research Society, Scientist Development Grant from the American Heart Association, NIH Transformative Research Award by NIH, and a recipient of Brain Pool Program in Korea.